Entera Bio (NASDAQ:ENTX) CEO Miranda Jayne Toledano Purchases 11,000 Shares of Stock

Entera Bio Ltd. (NASDAQ:ENTX) CEO Miranda Jayne Toledano acquired 11,000 shares of the company’s stock in a transaction dated Monday, December 29th. The shares were bought at an average price of $1.81 per share, for a total transaction of $19,910.00. Following the purchase, the chief executive officer owned 426,575 shares in the company, valued at approximately $772,100.75. This represents a 2.65% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Entera Bio Trading Up 11.1%

NASDAQ:ENTX opened at $2.00 on Wednesday. Entera Bio Ltd. has a 1-year low of $1.50 and a 1-year high of $3.22. The firm has a fifty day simple moving average of $2.37 and a 200 day simple moving average of $2.12. The stock has a market capitalization of $91.71 million, a PE ratio of -8.00 and a beta of 1.71.

Entera Bio (NASDAQ:ENTX) last posted its quarterly earnings results on Friday, November 14th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.02. Entera Bio had a negative net margin of 4,525.11% and a negative return on equity of 67.56%. On average, equities analysts predict that Entera Bio Ltd. will post -0.28 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in ENTX. Bessemer Group Inc. bought a new stake in shares of Entera Bio in the second quarter valued at about $268,000. HighTower Advisors LLC raised its stake in Entera Bio by 53.3% in the 1st quarter. HighTower Advisors LLC now owns 18,140 shares of the company’s stock worth $31,000 after purchasing an additional 6,310 shares in the last quarter. Parkman Healthcare Partners LLC boosted its holdings in Entera Bio by 6.3% in the 1st quarter. Parkman Healthcare Partners LLC now owns 439,632 shares of the company’s stock valued at $747,000 after purchasing an additional 25,900 shares during the period. Finally, Citadel Advisors LLC grew its position in shares of Entera Bio by 243.0% during the 3rd quarter. Citadel Advisors LLC now owns 39,978 shares of the company’s stock worth $77,000 after purchasing an additional 28,322 shares in the last quarter. Institutional investors own 14.11% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on ENTX. Weiss Ratings reissued a “sell (d-)” rating on shares of Entera Bio in a research report on Wednesday, October 8th. Wall Street Zen upgraded Entera Bio to a “sell” rating in a research note on Saturday. One research analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $10.00.

About Entera Bio

Entera Bio, Inc is a clinical‐stage biopharmaceutical company pioneering the development of orally delivered peptide therapeutics. Utilizing its proprietary oral delivery platform, Entera Bio seeks to overcome the challenges of gastrointestinal absorption for large peptide molecules. The technology is designed to facilitate transit across the intestinal epithelium while preserving peptide structure and bioactivity, offering the potential for daily oral dosing in lieu of injectable formulations.

The company’s lead candidate, EB613, is an oral parathyroid hormone (PTH) analog under investigation for the treatment of osteoporosis.